Lawitz 2014a

Methods	Randomised clinical trial
Participants	100 participants Sex: 65 men, 35 women Country: USA Inclusion criteria: compensated cirrhotic adults with chronic HCV genotype 1 infection. Exclusion criteria: not described.
Interventions	Experimenatal group: oral 250 mg of GS‐9669 once daily for 8 weeks or oral 500 mg of GS‐9669 once daily for 8 weeks. Control group: RBV. Co‐intervention: ledipasvir and sofosbuvir.
Outcomes	Adverse events, HCV RNA SVR12
Notes	We emailed Lawitz and colleagues on 26 April 2016 for additional information on random, blinding, missing data, protocol, data separate from the groups, participants characteristics, funding, IL28b‐databut reply not received yet.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	No protocol could be obtained
Vested‐interest bias	High risk	Several authors worked for several pharmaceutical companies
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias